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INTRODUCTION
Women often report delight after giving birth (Bina, 2008) , but when they develop postpartum depression (PPD), it is far from delightful. For postpartum women with depressive symptoms and their health care providers, it is important to differentiate postpartum depressive symptoms from other symptoms that occur in the postpartum period that are normative of childbirth. Pregnancy induces changes in many body functions, so the majority of changes, or symptoms, that postpartum women experience are the body's way of reverting to a normal, nonpregnant state. These symptoms typically last for six weeks following delivery, although some can last longer. For example, alterations in sleep can occur for months after delivery (Blackburn, 2013) , and poor sleep quality is a risk factor for PPD (Okun, 2015; Okun et al., 2011; Wu et al., 2014) . Further, sleep deprivation is associated with higher levels of pro-inflammatory cytokines, which is important because higher plasma concentrations of pro-inflammatory cytokines are associated with PPD (Chang, Pien, Duntley, & Macones, 2010) . Changes in sleeping patterns are an appropriate PPD screening instrument for use with AI/AN women. Specific aims were to: 1) systematically examine and analyze the psychometric properties of the PHQ-9 when screening for PPD in a variety of samples of ethnic minority women and women from non-Western cultures; 2) systematically examine and analyze the psychometric properties of the EPDS in similar samples; and 3) compare and contrast the psychometric properties of the PHQ-9 to those of the EPDS when screening for PPD in culturally diverse samples of women, and specifically AI/AN women.
Background and Significance
Postpartum depression affects about one in seven new mothers in the U.S. (O'Hara & McCabe, 2013) . While there is some disagreement as to when it begins or how long it persists, PPD is clinically defined as a major depressive episode that occurs any time up to one year following childbirth (American Psychiatric Association [APA], 2013; O'Hara & McCabe, 2013) .
Its adverse maternal, infant/child, and family effects (Horwitz, Briggs-Gowan, Storfer-Isser, & Carter, 2007; Miklush & Connelly, 2013 ) increase use of health care resources, which indirectly impacts global society (Agency for Healthcare Research and Quality, 2013) . This chain of influence is linked to maternal symptoms of guilt and despair, depressed mood, and fatigue (APA, 2013; O'Hara & McCabe, 2013) . As one might expect, these symptoms negatively influence the mother-infant relationship, causing insecure attachment (Hennighausen & LyonsRuth, 2007) . Attachment disorders can lead to aggression in the child during school-aged years (Hennighausen & Lyons-Ruth, 2007; Klaus & Kennell, 1976) and psychopathology in late adolescence (Hennighausen & Lyons-Ruth, 2007 ) that ultimately leads to more financial and social demands on the societal whole.
Screening for Postpartum Depression
The U.S. Department of Health and Human Services' (USDHHS) Healthy People 2020 initiative for health promotion and disease prevention has recently added an objective for reducing the rate of PPD symptoms in the U.S. (USDHHS, 2016) . Additionally, in January 2016 the U. S. Preventive Services Task Force released an updated recommendation for depression screening in adults to include pregnant and postpartum women (Siu & U.S. Preventive Services Task Force, 2016) . This is crucial, as screening for depression in postpartum women is associated with improved outcomes. More specifically, depression-screening programs for pregnant and postpartum women reduce the prevalence of depression, increase remission of depression symptoms, and increase treatment response (O'Connor et al., 2016; Siu & U.S. Preventive Services Task Force, 2016) . Research suggests that early identification or detection is key in the treatment of PPD (Hanna et al., 2004) , so there is clear benefit to screening for depression in postpartum women.
MATERIALS AND METHODS
This integrative review serves as a comparative instrument analysis examining validation studies of the EPDS and the PHQ-9 to identify an appropriate PPD screening instrument for AI/AN women in the U.S. By extension, strengths and weaknesses of the PPD literature surrounding screening are highlighted. This is a necessary step toward improving the PPD knowledge base (Torraco, 2005) .
Search Strategy
The search strategy included Medline Complete, PsychARTICLES, Embase, PubMed, 
Data Evaluation and Analysis
The literature search produced 58 articles investigating PPD using either the EPDS or the PHQ-9 as the screening instrument in samples of culturally diverse women and represented several disciplines including nursing, psychology, medicine (mostly psychiatry), public health, social work, education, political science, pharmacy, and epidemiology (see Appendix Tables A1   and A2 ). All abstracts were read to identify relevant reports. Any studies deemed relevant (or if relevance was uncertain) were read in full, and studies were categorized according to the screening instrument used. The selected studies were evaluated in terms of level of evidence using the American Association of Critical-Care Nurses (AACN) system (see Table 1 ; Armola et al., 2009) . Lastly, the psychometric performance of the EPDS and the PHQ-9 was critiqued for each study reviewed (see Tables 5-8) . 
RESULTS
Findings are categorized according to format, reliability, concurrent validity, predictive validity, and predictive accuracy. Findings from studies using the PHQ-9 and the EPDS are compared and contrasted within each category.
Format

PHQ-9
The PHQ-9 was developed in 2001 and is intended to screen for a variety of depressive disorders, such as major depressive disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV; Kroenke et al., 2001) . It is a nine-item, self-report scale that can be completed in less than five minutes (see Table 2 ; Kroenke et al., 2001) . Unlike the EPDS, it does not exclude common somatic symptoms of the postpartum period, thereby lowering specificity when screening for PPD in women. Originally validated in a sample of 580 primary care (male and female) and OB-GYN (female) clinic patients in the U.S., the authors suggested a cut-off score of 10 (Kroenke et al., 2001 ). While only a few studies assess the psychometric properties of the PHQ-9 when screening specifically for PPD (n = 7), this instrument has been validated in other samples as a reliable and valid instrument for screening for other depressive disorders (Arroll et al., 2010; Martin, Rief, Klaiberg, & Braehler, 2005) . It is now available in over 30 other languages, including Arabic (Sawaya, Atoui, Hamadeh, Zeinoun, & Hahas, 2016) , Chinese (Yeung et al., 2008) , and Korean (Shin et al., 2010) .
EPDS
The EPDS was created in 1987 and has been used globally to screen for PPD (Cox et al., 1987) . It is a ten-item, self-report scale that can be completed in less than five minutes (see Table   2 ; Cox et al., 1987) . The EPDS was born from the need for a depression screening scale with fewer limitations when used with childbearing women. In particular, authors were interested in placing less emphasis on somatic symptoms of depression, such as sleep disturbances and fatigue, because they are relatively common and can be normal findings in the postpartum period. In reducing the emphasis on these somatic symptoms, the EPDS was the first instrument to screen specifically for PPD, thereby increasing specificity. It was originally validated in a sample of 84 postpartum women in an out-of-hospital setting in England; the authors suggested a cut-off score of 9/10 (Cox et al., 1987) . It is now available in 23 other languages, including Greek (Leonardou et al., 2009) , Hungarian (Töreki et al., 2014) , and Sudanese (Khalifa, Glavin, Bjertness, & Lien, 2015) and has also been validated in samples of fathers (Loscalzo, Giannini, Contena, Gori, & Benvenuti, 2015) and adolescent mothers (Logsdon & Myers, 2010) . Table 3 shows a summary of the reliability of the PHQ-9 and EPDS when screening for PPD from the studies reviewed (n = 58). While the reviewed studies included seven using the PHQ-9 and 54 using the EPDS, not all studies reported reliability values or statistics. For example, some reported internal consistency and no sensitivity, specificity, positive predictive value, or negative predictive value, while others reported all five values. Of the 58 studies reviewed, 37 reported some or all reliability information, with three using the PHQ-9 and 36 using the EPDS.
Internal consistency is one component of reliability and speaks to the extent to which the items on a scale are 1) interrelated and 2) all measuring the same attribute (Polit & Yang, 2016) .
Internal consistency is measured by computing Cronbach's alpha (ɑ), and values of .70 and higher are desirable (Adams & Lawrence, 2015; DeVellis, 2017) . In terms of screening for PPD,
internal consistency values were above .70 for both tools and were, therefore, acceptable (see Table 3 ).
Another approach to establishing internal consistency is split-half reliability (Adams & Lawrence, 2015) , which offers a method of determining test-retest reliability without administering the test twice (Grove, Burns, & Gray, 2013) . Test-retest reliability speaks to the degree to which scores can be replicated with repeated administrations of the tool (Polit & Yang, 2016) . There are no reports of split-half or test-retest reliability for the PHQ-9 when used to screen for PPD; however, in its original validation study, test-retest reliability was reported as "excellent," yet no value was given. For the EPDS, split-half reliability (Pearson's r) and testretest reliability were acceptable (see Table 3 ). Based on biostatistician guidelines, Pearson's r values above .70 are generally acceptable (Adams & Lawrence, 2015) , and ICC values above .60 are generally acceptable (Cicchetti, 1994) . 
Concurrent Validity of the PHQ-9 to the EPDS
Concurrent validity is demonstrated when a test correlates well with an instrument that has previously been validated (Polit & Yang, 2016) , and two studies report on this validity for the PHQ-9 and the EPDS in women (see Table 4 ). Both report acceptable correlations, but it is noteworthy that in the Hanusa, Scholle, Hakett, Spadaro, and Wisner (2008) study 72 percent of the sample was Caucasian. In addition, Flynn, Sexto, Ratliff, Porter, and Zivin (2011) used summary scoring for the acceptable Pearson's r. When PHQ-9 diagnostic scoring was used, the degree of agreement between the EPDS and the PHQ-9 (k >.7) was only 0.5 for postpartum women (Flynn et al., 2011 ). It appears that correct identification of the diagnostic group was reduced due to decreased sensitivity in using this method (diagnostic versus summary scoring). Yawn et al. (2009) reported 17 percent discordance between the EPDS and the PHQ-9. It seems as though the two screening tools, when screening for PPD, are categorizing differently. Predictive Validity Table 5 displays a summary of the predictive validity of the PHQ-9 and the EPDS when screening for PPD from the studies reviewed (n = 58). Again, not all studies reported validity values or statistics. Of the 58 studies reviewed, 49 reported some or all predictive validity values or statistics, with five using the PHQ-9 and 47 using the EPDS. Both instruments had comparable sensitivity in screening for PPD in the studies reviewed. As might be expected due to the inclusion of items related to somatic symptoms of depression, the PHQ-9 had reduced specificity when screening for PPD as compared to the EPDS. 
Predictive Accuracy
The EPDS excludes common symptoms of the postpartum period such as fatigue, but discriminative validity for detecting PPD in samples of women drawn from non-Western cultures is low (see Table 6 ). Table 6 ). Finally, for the PHQ-9, discriminative validity for detecting PPD in culturally diverse samples of women is extremely limited, as only one study was found that reported psychometric properties of the EPDS in screening for PPD, and it was conducted outside the U.S. (see Table 6 ; Weobong et al., 2009 ). 
DISCUSSION
Both the PHQ-9 and the EPDS are intended to screen for depression and are quick and easy to complete. Neither scale has been normed, but there have been recommended cut-off scores established for both (Cox et al., 1987; Kroenke et al., 2001) . With the EPDS, more false positives are possible, with a greater likelihood to diagnosis women without PPD as having PPD.
Clinically, this is good for screening, assuming the cost of workup and treatment outweighs the cost of starting women on the treatment regimen and labeling them with a disorder they do not have. In terms of research, this can be problematic for finding women that meet inclusion criteria.
While possessing excellent concurrent validity, the low predictive accuracy of both instruments in samples of culturally diverse women suggests a cultural bias, where perhaps the terms used in the scales are not meaningful and/or PPD is viewed, characterized, or manifested differently in these cultures of women. The low predictive accuracy could also be attributed to underreporting. The EPDS is far more validated for PPD screening than the PHQ-9, yet neither instrument has been cross-culturally adapted or validated for PPD screening with AI/AN women.
Neither instrument may be appropriate for use in this population, so investigators should examine psychometric properties of both instruments before using them with AI/AN and other underrepresented ethnic minority populations in the U.S.
Issues with PPD screening in AI/AN women may contribute to inaccurate and unreliable
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Copyright: Centers for American Indian and Alaska Native Health Colorado School of Public Health/University of Colorado Anschutz Medical Campus (www.ucdenver.edu/caianh) prevalence reporting. There are no studies that report on PPD screening in AI/AN women, and no PPD or general depression screening instruments have been validated or otherwise psychometrically evaluated to screen for PPD in AI/AN women. PPD in underrepresented ethnic minorities is a public health priority in the U.S., complicated by what appears to be a stark racial/ethnic disparity. The absence of a culturally and/or linguistically appropriate screening tool raises concern for the accuracy of PPD prevalence reports for AI/AN women. The PHQ-9 needs more validation in screening for PPD in diverse samples of women. Validation of the EPDS and/or the PHQ-9 in underrepresented ethnic minority women in the U.S., particularly AI/AN women, will assist in accurately assessing PPD prevalence in these populations. Finally, despite the issues with PPD screening for AI/AN women (including the need for further research), it is still clinically important that AI/AN women are screened for PPD, that appropriate referrals to care are made when indicated, and that follow-up is accomplished in a timely and unwavering fashion. These steps are vital to improve PPD care for AI/AN women.
Cross-cultural research has been conducted for hundreds of years, resulting in a massive and varied body of literature. More specifically, cross-cultural research has focused on measurement and scale development issues for decades. For example, Flaherty et al. (1988) proposed five steps for accomplishing cross-cultural equivalence in the context of instrument adaptation. More recently, Sidani, Guruge, Miranda, Ford-Gilboe, and Varcoe (2010) developed a five-phase, integrative method for exploring conceptual equivalence (as part of the process of cross-culturally adapting and translating instruments) during their work concerning the health effects of intimate partner violence in Sri Lankan Tamil women.
Given the issues surrounding PPD prevalence in AI/AN women, a logical next step is determining the cross-cultural validity of a widely used, globally validated PPD screening instrument such as the EPDS in a sample of AI/AN women. Cross-cultural adaptation advances the science of comparative effectiveness research in the area of PPD in AI/AN women, and therefore a logical next step is conceptual equivalence of PPD for these women. Equivalence concerns the degree to which an adapted and/or translated measure is comparable to the original measure (Polit & Yang, 2016) . Conceptual equivalence is a more specific type of equivalence that is concerned with whether the concept being measured even exists in the target culture, and if so, its relevance and the extent to which it has similar meaning in that culture (Polit & Yang, 2016; Sidani et al., 2010) between the source (the culture in which the concept and measure were originally developed) and target cultures, and the other end represents zero percent agreement -where the concept does not exist in the target culture (Polit & Yang, 2016; Sidani et al., 2010) . While there are other types of equivalence to consider in adapting an instrument, conceptual equivalence is the most important, and often the first step in the cross-cultural adaptation process (Gjersing, Caplehorn, & Clausen, 2010; Polit & Yang, 2016; Sidani et al., 2010; Waltz, Strickland, & Lenz, 2010) .
Limitations for this review are few. The major limitation was prohibiting prenatal/antenatal depression research from inclusion, because many investigations combine prenatal and postpartum depression as various measures or variables. However, research surrounding PPD in AI/AN women is severely limited, and research regarding prenatal depression in AI/AN women is nonexistent. Therefore, PPD was chosen as the primary focus for this review.
Future Directions
The literature reveals a variety of interventions for PPD treatment; currently, standard PPD treatment involves antidepressant medication, psychotherapy, or both (Dennis & Dowswell, 2013) . However, no studies report on the effectiveness of standard PPD treatment in AI/AN women. This lack of evidence substantiates the need for further research surrounding not only the effectiveness of standard PPD treatment for these women, but also desired and/or preferred treatments based on cultural preference. Exploring the acceptability, compatibility, and feasibility of integrating traditional native healing into current interventions and treatment for PPD with AI/AN women is another area for future investigation.
Lastly, future studies should explore the role of acculturation in AI/AN women's experiences of PPD, as level of acculturation may impact their PPD risk and therefore prevalence. Acculturation has been studied rarely in the context of PPD and not at all for AI/AN women in that same context. Results in studies examining the relationship between PPD and acculturation are contradictory. For example, Beck, Froman, and Bernal (2005) found no statistically significant relationship between acculturation and PPD or the presence of PPD symptoms. Yet other studies report with more acculturation, a woman's risk of PPD increases (Heilemann, Frutos, Lee, & Kury, 2004; Martinez-Schallmoser, Telleen, & MacMullen, 2003) .
These studies were conducted with Latina women, and no studies have been conducted that examine the relationship between acculturation and PPD in samples of AI/AN women. This begs the question: Does a relationship exist between acculturation and PPD for AI/AN women?
Further, the type of relationship may depend upon the cultural traditions and beliefs to which AI/AN women more strongly ascribe. Furthermore, acculturation scales have not been validated in samples of AI/AN women. Given that acculturation has been associated with an increased risk of PPD in other minority women, it is possible that the same will be true for AI/AN women. Perhaps a woman's level of acculturation could be a partial explanation for the disparity seen in PPD prevalence, where AI/AN women have higher rates than the general U.S. population of women. There is a compelling need for further PPD research with AI/AN women.
CONCLUSION
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